Cutaneous T-Cell Lymphoma(CTCL) - Market Insight, Epidemiology and Market Forecast - 2027

Cutaneous T-Cell Lymphoma(CTCL) - Market Insight, Epidemiology and Market Forecast - 2027

  • Pages: 154
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Jul, 2018
  • SKU: DIMI0091
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Cutaneous T-cell lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CTCL in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. 
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cutaneous T-cell lymphoma (CTCL) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2016-2027

Cutaneous T-cell lymphoma (CTCL) - Disease Understanding and Treatment Algorithm
The DelveInsight Cutaneous T-cell lymphoma (CTCL) market report gives the thorough understanding of the Cutaneous T-cell lymphoma (CTCL) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cutaneous T-cell lymphoma (CTCL) in the US, Europe, and Japan.

Cutaneous T-cell lymphoma (CTCL) Epidemiology
The Cutaneous T-cell lymphoma (CTCL) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken. 
The disease epidemiology covered in the report is segmented by sub-type [Mycosis Fungoides and Others (Sezary syndrome, Primary cutaneous peripheral T-cell lymphoma, unspecified, ATLL, primary cutaneous CD30+ T-cell lymphoproliferative disorders and subcutaneous panniculitis-like T-cell lymphoma (SPTCL)], gender-specific and stage-specific [early stage (IA, IB and IIA) and late stage (IIA, III, IVA and IVB)]
According to DelveInsight, the incident cases of CTCL in 7 major markets was 8,310  in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM United States account for highest incident population of CTCL i.e., 3,207 followed by United Kingdom. 

Cutaneous T-cell lymphoma (CTCL) Drug Chapters
This segment of the Cutaneous T-cell lymphoma (CTCL) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently there are six marketed drugs available for the treatment of CTCL including Istodax (Romidepsin), Poteligeo (Mogamulizumab), Valchlor (Mechlorethamine), Uvadex (Methoxsalen), Targretin (Bexarotene) and Zolinza (Vorinostat). Detailed chapters for all of these drugs, along with the promising upcoming therapies including SGX301 (Soligenix Inc), Adcetris (Brentuximab Vedotin), Resminostat (4SC AG) etc have been covered in the report.

Cutaneous T-cell lymphoma (CTCL) Market Outlook
The Cutaneous T-cell lymphoma (CTCL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
According to DelveInsight, the 7MM market of Cutaneous T-cell lymphoma (CTCL) was USD 353.5 million in 2016, and is expected to increase at a significant growth during the study period i.e., 2016-2027.

Cutaneous T-cell lymphoma (CTCL) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cutaneous T-cell lymphoma (CTCL) Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Cutaneous T-cell lymphoma (CTCL) Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake 

• Highly Analyzed Market

• Key Cross Competition

Cutaneous T-cell lymphoma (CTCL) Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Cutaneous T-cell lymphoma (CTCL) market

• Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-cell lymphoma (CTCL) market

• To understand the future market competition in the Cutaneous T-cell lymphoma (CTCL) market.

1. Report Introduction 2
2. Cutaneous T- Cell Lymphoma Market Overview at a Glance 16
2.1. Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2017 16
2.2. Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2027 16
3. Cutaneous T- Cell Lymphoma Overview 17
3.1. Introduction 17
3.2. Types 17
3.3. Causes 18
3.4. Pathophysiology 19
3.5. Symptoms 19
3.6. Diagnosis 20
4. Epidemiology of Cutaneous T-Cell Lymphoma 22
4.1. United States 22
4.1.1. Assumptions and Rationale 22
4.1.2. Incident Population of Cutaneous T-Cell Lymphoma 22
4.1.3. Treatable Cases of Cutaneous T-Cell Lymphoma in the United States 24
4.1.4. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the United States 25
4.1.5. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the United States 26
4.1.6. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the United States 27
4.1.7. Early Stage Specific Incidence of CTCL in the United States 28
4.1.8. Late Stage Specific Incidence of CTCL in the United States 29
4.2. Europe 30
4.3. Assumptions and Rationale 30
4.3.1. Germany 31
4.3.1.1. Incident Population of Cutaneous T-Cell Lymphoma in Germany 32
4.3.1.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Germany 33
4.3.1.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany 34
4.3.1.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany 35
4.3.1.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany 36
4.3.1.6. Early Stage Specific Incidence of CTCL in the Germany 37
4.3.1.7. Late Stage Specific Incidence of CTCL in the Germany 38
4.3.2. France 39
4.3.2.1. Incident Population of Cutaneous T-Cell Lymphoma in France 40
4.3.2.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the France 41
4.3.2.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France 42
4.3.2.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France 43
4.3.2.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France 44
4.3.2.6. Early Stage Specific Incidence of CTCL in the France 45
4.3.2.7. Late Stage Specific Incidence of CTCL in the France 46
4.3.3. Italy 47
4.3.3.1. Incident Population of Cutaneous T-Cell Lymphoma in Italy 47
4.3.3.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Italy 48
4.3.3.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy 49
4.3.3.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy 50
4.3.3.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy 51
4.3.3.6. Early Stage Specific Incidence of CTCL in the Italy 52
4.3.3.7. Late Stage Specific Incidence of CTCL in the Italy 53
4.3.4. Spain 54
4.3.4.1. Incident Population of Cutaneous T-Cell Lymphoma in Spain 55
4.3.4.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Spain 56
4.3.4.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain 57
4.3.4.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain 58
4.3.4.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain 59
4.3.4.6. Early Stage Specific Incidence of CTCL in the Spain 60
4.3.4.7. Late Stage Specific Incidence of CTCL in the Spain 61
4.3.5. United Kingdom 62
4.3.5.1. Incident Population of Cutaneous T-Cell Lymphoma in UK 62
4.3.5.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the United Kingdom 63
4.3.5.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom 64
4.3.5.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom 65
4.3.5.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK 66
4.3.5.6. Early Stage Specific Incidence of CTCL in the UK 66
4.3.5.7. Late Stage Specific Incidence of CTCL in the UK 67
4.4. Japan 68
4.4.1. Incident Population of Cutaneous T-Cell Lymphoma in Japan 69
4.4.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Japan 70
4.4.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan 71
4.4.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan 72
4.4.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan 73
4.4.6. Early Stage Specific Incidence of CTCL in the Japan 74
4.4.7. Late Stage Specific Incidence of CTCL in the Japan 75
5. Treatment Algorithm 76
5.1. International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas 81
5.2. United States 82
5.3. NCCN Guidelines 82
5.4. Europe 87
5.5. ESMO Guidelines 87
5.6. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines 88
5.7. EORTC recommendations for the treatment of mycosis fungoides/Se´zary syndrome 89
6. Unmet Needs 91
7. Marketed Drugs 92
7.1. Istodax (Romidepsin): Celgene Corporation 93
7.1.1. Drug Description 93
7.1.2. Mechanism of Action 93
7.1.3. Advantages & Disadvantages 93
7.1.4. Safety and Efficacy 93
7.1.5. Product Profile 94
7.2. Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd. 95
7.2.1. Drug Description 95
7.2.2. Mechanism of Action 95
7.2.3. Advantages & Disadvantages 95
7.2.4. Safety and Efficacy 96
7.2.5. Product Profile 96
7.3. Valchlor/ Ledaga (Mechlorethamine): Actelion 97
7.3.1. Drug Description 97
7.3.2. Mechanism of Action 97
7.3.3. Advantages & Disadvantages 97
7.3.4. Safety and Efficacy 98
7.3.5. Product Profile 98
7.4. Uvadex (Methoxsalen): Mallinckrodt Pharmaceuticals 99
7.4.1. Drug Description 99
7.4.2. Mechanism of Action 99
7.4.3. Advantages & Disadvantages 99
7.4.4. Safety and Efficacy 100
7.4.5. Product Profile 100
7.5. Targretin (Bexarotene): Eisai Co., Ltd. 101
7.5.1. Drug Description 101
7.5.2. Mechanism of Action 101
7.5.3. Advantages & Disadvantages 101
7.5.4. Safety and Efficacy of Targretin 102
7.5.5. Product Profile 102
7.6. Zolinza (Vorinostat): Merck Sharp & Dohme Corp. 103
7.6.1. Drug Description 103
7.6.2. Mechanism of Action 103
7.6.3. Advantages & Disadvantages 103
7.6.4. Safety and Efficacy of Zolinza 104
7.6.5. Product Profile 104
8. Emerging Drugs 105
8.1. Phase-III Drugs Analysis – Monoclonal Antibodies and Photodynamic Therapy 105
8.2. Phase-II Drugs Analysis - Histone Deacetylase (HDAC) Inhibitors 106
9. Emerging Therapies 107
9.1. Brentuximab Vedotin: Seattle Genetics 107
9.1.1. Product Description 107
9.1.2. Research and Development 108
9.1.3. Product Development Activities 110
9.1.4. Product Profile 111
9.2. SGX301: Soligenix 112
9.2.1. Product Description 112
9.2.2. Research and Development 112
9.2.3. Product Development Activities 113
9.2.4. Product Profile 113
9.3. Quisinostat: Janssen 114
9.3.1. Product Description 114
9.3.2. Research and Development 114
9.3.3. Product Development Activities 115
9.3.4. Product Profile 115
9.4. Resminostat: 4SC AG 116
9.4.1. Product Description 116
9.4.2. Research and Development 116
9.4.3. Product Development Activities 118
9.4.4. Product Profile 118
9.5. Remetinostat: Medivir AB 119
9.5.1. Product Description 119
9.5.2. Research and Development 119
9.5.3. Product Development Activities 120
9.5.4. Product Profile 120
10. Cutaneous T- Cell Lymphoma: Country-Wise Market Analysis 121
10.1. Total Market Size of Early Stage Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027 121
10.2. Total Market Size of Late Stage Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027 122
10.3. Total Market Size of Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027 123
10.4. Assumptions and Caveats (7MM) 124
10.5. United States 126
10.5.1. Market Outlook 126
10.5.2. Stage Specific Market Size of CTCL in United States 128
10.5.3. Market Size of CTCL in United States 129
10.6. Europe 130
10.6.1. Market Outlook 130
10.6.2. Germany 132
10.6.2.1. Stage Specific Market Size of CTCL in Germany 132
10.6.2.2. Market Size of CTCL in Germany 134
10.6.3. France 135
10.6.3.1. Stage Specific Market Size of CTCL in France 135
10.6.3.2. Market Size of CTCL in France 137
10.6.4. Italy 138
10.6.4.1. Stage Specific Market Size of CTCL in Italy 138
10.6.4.2. Market Size of CTCL in Italy 140
10.6.5. Spain 141
10.6.5.1. Stage Specific Market Size of CTCL in Spain 141
10.6.5.2. Market Size of CTCL in Spain 142
10.6.6. United Kingdom 143
10.6.6.1. Stage Specific Market Size of CTCL in United Kingdom 143
10.6.6.2. Market Size of CTCL in United Kingdom 144
10.7. Japan 145
10.7.1. Market Outlook 145
10.7.2. Stage Specific Market Size of CTCL in Japan 147
10.7.3. Market Size of CTCL in Japan 148
11. Market Drivers 149
12. Market Restraints 150
13. Appendix 151
14. Report Methodology 151
14.1. Sources Used 
15. DelveInsight Capabilities 153
16. Disclaimer 154
17. About DelveInsight 154

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61
Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68
Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80
Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88
Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91
Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120
Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121
Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122
Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123
Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Table 61: United Kingdom  Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46
Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59
Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60
Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61
Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62
Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63
Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64
Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65
Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66
Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68
Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69
Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70
Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71
Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73
Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74
Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75
Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76
Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81
Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82
Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82
Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83
Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84
Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84
Figure 51:Treatment for Lymphomatoid papulosis 85
Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87
Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127
Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128
Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132
Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133
Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135
Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136
Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138
Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139
Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140
Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141
Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142
Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143
Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146
Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147

 

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22
Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23
Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24
Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25
Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27
Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28
Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31
Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32
Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33
Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34
Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36
Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37
Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39
Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40
Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41
Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42
Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44
Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45
Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46
Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47
Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48
Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49
Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51
Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52
Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54
Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55
Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56
Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57
Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell